<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02627859</url>
  </required_header>
  <id_info>
    <org_study_id>13DUR502</org_study_id>
    <nct_id>NCT02627859</nct_id>
  </id_info>
  <brief_title>26 Week Open Label Study Evaluating Single IA Injection of DUROLANE SJ for Treatment of Osteoarthritis Pain of the Ankle</brief_title>
  <official_title>A 26 Week Multicenter Prospective Open Label Clinical Study Evaluating a Single Intra-articular Injection of DUROLANE SJ1ml for Treatment of OA Pain of the Ankle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioventus LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioventus LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      26 week open label study of treatment with Durolane for OA pain of the ankle
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single injection Durolane in patients with mild to moderate OA of the ankle.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AOS pain subscale score</measure>
    <time_frame>at 26 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Durolane SJ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durolane SJ intra-articular injection; device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Durolane SJ</intervention_name>
    <description>1ml single intra-articular injection in ankle</description>
    <arm_group_label>Durolane SJ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females or males between the ages of 19 and 85 years of age

          2. Diagnosis of mild to moderate (K-L grade II or III) osteoarthritis (OA) of the study
             ankle joint, confirmed by radiographs taken within the previous six months OA in the
             contralateral ankle is permissible provided that OA symptoms are greater in the study
             ankle.

          3. VAS (100mm) AOS pain subscale score in the range of 30mm to 90mm for the study ankle

          4. Must be willing to discontinue use of oral and topical analgesia other than rescue use
             of acetaminophen for any pain including OA pain in the study ankle. Must also be
             willing to discontinue acetaminophen rescue medication for at least 24 hours before
             each study visit

          5. Abstinence from any IA or peri-articular injections in the study ankle during the
             course of the trial, except for the Investigational Product

          6. Cooperative and able to communicate effectively with the Investigators

          7. Patients with chronic ankle pain of the study ankle lasting more than 6 months without
             clinically significant improvement in ankle pain over the past one month

          8. Body mass index (BMI) â‰¤ 35 kg/m2.

          9. English literacy and ability to understand and complete all informed consent
             procedures

        Exclusion Criteria:

          1. Significant pain from other joints or low back pain requiring chronic ongoing
             analgesic therapy

          2. Hindfoot deformities

          3. Substantial venous or lymphatic stasis in the legs

          4. Presence of one or more conditions that could confound pain and functional assessments
             in the study ankle, e.g., plantar fasciitis, Achilles tendonitis, sprains of the foot,
             or degenerative joint disease of the foot.

          5. Clinically-apparent tense effusion, signs of misalignment or instability in the study
             ankle

          6. Ankle x-ray findings of acute fractures, severe loss of bone density, avascular
             necrosis and/or severe deformity in the study ankle

          7. Surgery to the study ankle within the previous 12 months

          8. Unable to abstain treatment with NSAIDs or any pain management medications during the
             week (or five half-lives of the drug, whichever is longer) prior to Baseline Visit.

          9. Unable to abstain from treatment with topical analgesics during the washout period
             prior to screening visit and throughout the duration of the study. Washout period for
             topical analgesics is based on clinical investigator judgment (~ a few days).

         10. Inability to tolerate acetaminophen for rescue medication use.

         11. IA or local peri-articular corticosteroid injections to the study ankle within the
             previous three months; or to any other joint within the previous month; or any oral
             corticosteroid within the previous month. Steroid inhalants are permitted if the
             patient has been on a stable regimen for the past month and remains on this regimen
             throughout the course of the trial

         12. IA injections with hyaluronic acid in the study ankle within the last 9 months

         13. Previous allergic reaction to a HA or lidocaine product allergies.

         14. Treatment with glucosamine/chondroitin sulfate initiated within the past three months,
             or dosage not stable for the past three months

         15. Change in physical therapy for the study ankle within one month preceding screening,
             or expected change in physical therapy for the ankle during the study

         16. Planned surgical procedure during the study period.

         17. Previous history or presence of septic arthritis in study ankle

         18. Active skin disease or infection in the area of the injection site

         19. Alcohol or drug abuse as determined by the Investigator or use of alcohol for control
             of pain; Use of illicit drugs including cannabis.

         20. Systemic inflammatory condition or autoimmune disease or infection such as rheumatoid
             arthritis, inflammatory arthritis, ankylosing spondylitis, psoriatic arthritis,
             reactive arthritis, gout/ acute pseudo gout or any other connective tissue disease

         21. Uncontrolled hypothyroidism

         22. Treatment with anticoagulant (except for acetylsalicylic acid maximum of 325mg/day)

         23. Any medical condition which in the opinion of the investigator makes the patient
             unsuitable for inclusion (e.g., severe progressive chronic disease, malignancy,
             bleeding disorder, fibromyalgia)

         24. Pregnant or breast-feeding woman or woman of child-bearing potential not practicing
             adequate contraception.

         25. Subjects that in the opinion of the investigator are unsuitable for inclusion (e.g.,
             subjects not likely to avoid other therapies, subjects not likely to stay in the study
             or with plans to relocate during the whole study period, or subjects likely to be
             unreliable)

         26. Concurrent participation in any other clinical study or participation within the
             preceding 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alistair Younger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Pauls Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Providence Health Care</name>
      <address>
        <city>Vancouver,</city>
        <state>British Columbia</state>
        <zip>V6Z-2A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2015</study_first_submitted>
  <study_first_submitted_qc>December 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2015</study_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

